Preferred Label : Semaglutide;
NCIt definition : A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human
GLP-1 (7-37), with antihyperglycemic and appetite regulating activities. Upon administration,
semaglutide binds to and activates GLP-1 receptor. In pancreatic beta cells, this
increases glucose-dependent insulin release. Semaglutide also reduces the elevated
glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying.
Altogether this lowers the postprandial glucose level. In the brain, the binding to
and activation of GLP-1 receptor suppresses appetite, which decreases caloric intake
and lowers body weight. GLP-1 is normally secreted by L cells of the gastrointestinal
(GI) mucosa in response to a meal to normalize blood glucose levels. It also plays
an important role in the regulation of appetite and caloric intake.;
UNII : 53AXN4NNHX;
InChIKey : DLSWIYLPEUIQAV-CCUURXOWSA-N;
CAS number : 910463-68-2;
Drug name : Ozempic; Wegovy; Rybelsus;
NCI Metathesaurus CUI : CL553532;
Origin ID : C152328;
UMLS CUI : C3885068;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
concept_is_in_subset
https://minerva-ebp.be/FR/Article/2387
2024
Belgium
critical appraisal or critical reading
obesity
adulthood
Usual Severity Weight Loss
Obese
semaglutide
How Much Distress Weight Loss
Weight Lifting
Illinois
How Often Weight Loss
weight loss
Semaglutide
Interleukin
weight loss
semaglutide
Weight Loss
Overweight
Israel
What Month is it
mouth, nos
adult
Oral Cavity
Oral Route of Administration
Oral Dosage Form
Legal Adult
Have Weight Loss
decreased body weight
overweight
Weight Loss, CTCAE
---
https://www.usherbrooke.ca/baladocritique/archives/episode-59-etude-select
2024
Canada
sound
Diastolic Blood Pressure
semaglutide
Obesity, CTCAE
Cardiovascular Disorder
data collection
Off Study
obesity
disease of cardiovascular system, nos
breeding
Clinical Study
semaglutide
obesity
Obesity
Have Diabetes
Human Participant Protection Regulations
DICOM Study
obesity, nos
cardiovascular diseases
diabetes mellitus
persons
Semaglutide
Obese
On Study
---